Results 51 to 60 of about 5,463 (146)

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
In an ageing and inflamed haematopoietic ecosystem, clonal haematopoiesis and chronic lymphocytic leukaemia may originate from shared or parallel stem cell clones. This interaction modulates the effects of targeted therapies and contributes to cytopenias, cardiovascular toxicity, therapy‐related myeloid neoplasms and Richter transformation.
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy

Kidney International Reports
Introduction: B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II ...
Xiaole Su, Binxin Wu, Xuan Tie, Xiaojiao Guo, Rongrong Feng, Xi Qiao, Lihua Wang   +6 more
doaj   +1 more source

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Biologics: Targets & Therapy, 2015
Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj  

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia

Clinical Interventions in Aging, 2015
Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries ...
Seiter K, Mamorska-Dyga A
doaj  

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

Virology Journal
Background Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell depletion and superior in ...
Wenxiu Shu, Qianqian Yang, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Jiaqi Tong, Yanping Song, Bingrong Chen, Dengbing Chen, Dian Jin   +10 more
doaj   +1 more source

Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases

Frontiers in Immunology
ObjectiveRituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting ...
Wenyi Wu, Juan Wang, Sheng Chen
doaj   +1 more source

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

HemaSphere, Volume 10, Issue 3, March 2026.
Morgane Brocard, Damien Roos‐Weil, Lukshe Kanagaratnam, Thomas Hueso, Lucile Bussot, Benjamin Papoular, Cécile Tomowiak, Steeve Chevreux, Gilles Crochet, Tristan Vaugeois, Elise Toussaint, Simone Ferrero, Charalampia Kyriakou, Anne Quinquenel, Prashant Kapoor, Eric Durot   +15 more
wiley   +1 more source

Exploring the synergy between telomere length and genomic complexity in CLL

British Journal of Haematology, Volume 208, Issue 3, Page 1121-1126, March 2026.
Silvia Ramos‐Campoy, Anna Puiggros, Joanna Kamaso, Helen Parker, Gian Matteo Rigolin, Claudia Haferlach, María José Larráyoz, Rosa Collado, Rocío Salgado, María José Calasanz, Laurence Etter, Alberto Valiente, Pau Abrisqueta, Francesc Bosch, Eva Gimeno, Antonio Cuneo, Florence Nguyen‐Khac, Jacqueline Schoumans, Jonathan C. Strefford, Blanca Espinet   +19 more
wiley   +1 more source

The clinical development of obinutuzumab for the treatment of follicular lymphoma

Cancer Management and Research, 2017
Barbara Ma,1 Chaitra Ujjani2 1Department of Medicine, 2Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA Abstract: Impressive progress has been made in recent decades for advanced-stage follicular lymphoma ...
Ma B, Ujjani C
doaj